Selank: Mechanism, Evidence, and Dosing Protocols

Research disclaimer: Selank is sold for research purposes only and is not intended for human consumption. The information below is drawn from published scientific literature.

Evidence Tier

Human clinical trials in Russia — registered medicine for anxiety and asthenic disorders. Limited Western trial data. More human evidence than most nootropic peptides; less than established pharmaceutical anxiolytics.

Selank is an approved pharmaceutical in Russia and several post-Soviet states. It has been evaluated in multiple controlled trials, primarily conducted at the Institute of Molecular Genetics and the V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology. The quality of these trials by Western publication standards varies.

What Is Selank?

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a structural analog of tuftsin — a tetrapeptide fragment of IgG immunoglobulin (Thr-Lys-Pro-Arg) — with a C-terminal Pro-Gly-Pro stabilising extension.

Tuftsin itself was identified in the 1970s as having both immune-stimulating and CNS-modulating properties. The challenge was that native tuftsin is degraded within minutes by serum enzymes. The Pro-Gly-Pro extension that defines Selank prevents this degradation, extending the effective half-life sufficiently for intranasal administration to produce CNS effects.

Like Semax, Selank is administered intranasally and does not require injection.

Mechanism of Action

Enkephalin Stabilisation (Primary)

The most specific and well-documented mechanism of Selank is inhibition of the enzymes that degrade enkephalins — endogenous opioid peptides involved in emotional regulation, stress response, and reward. By slowing enkephalin breakdown, Selank extends the duration of endogenous calming and mood-regulating signals. This is mechanistically distinct from benzodiazepines (which enhance GABA-A receptor function) and from SSRIs (which block serotonin reuptake).

GABAergic Modulation

Selank modulates GABA-A receptor function, producing anxiolytic effects via the same receptor system as benzodiazepines — but through an indirect modulatory mechanism rather than direct allosteric binding. This likely explains some of the cross-tolerance and withdrawal data: Selank does not produce the dependence profile of benzodiazepines because it is not a direct GABA-A agonist.

Serotonergic and Dopaminergic Regulation

Selank increases serotonin turnover in several brain regions and modulates dopamine metabolism in the frontal cortex. The serotonergic effect contributes to mood stabilisation; the dopaminergic effect may explain why Selank does not produce the cognitive blunting that sedative anxiolytics cause.

Immune Modulation

Reflecting its tuftsin heritage, Selank has documented effects on immune function — stimulating T-cell activity and interferon production. This immune component is less relevant to its primary anxiolytic application but is a genuine pharmacological property that distinguishes it from synthetic anxiolytics.

Brain-Derived Neurotrophic Factor

Several studies report modest BDNF upregulation with Selank, though this effect is weaker and less consistent than with Semax. It may contribute to a mild neurotrophin-supporting effect that explains some of the cognitive reports alongside the anxiolytic activity.

What the Evidence Actually Shows

Generalised Anxiety Disorder

The primary clinical indication. Russian trials show significant anxiety reduction on standardised scales (Hamilton Anxiety Rating Scale) with Selank versus placebo or benzodiazepine comparators. The effect appears comparable to low-dose benzodiazepines in some trials without the sedation or dependence.

Asthenic Disorders

Asthenia — a syndrome of fatigue, cognitive fog, and low mood common in post-viral and post-injury states — is a documented indication. Selank reduces asthenic symptoms and improves subjective cognitive performance. This is one of the more clinically relevant applications for researchers interested in post-COVID or chronic fatigue presentations.

Anxiolysis Without Sedation

Multiple trials confirm the key differentiation: Selank reduces anxiety on objective measures without impairment of reaction time, working memory, or motor coordination. This has been tested specifically and confirmed in controlled settings. It is what makes Selank pharmacologically interesting — anxiolytics that do not impair cognition are valuable and rare.

No Physical Dependence

In animal models of dependence, Selank does not produce the physical dependence profile of benzodiazepines. Discontinuation does not produce withdrawal syndrome in chronic administration models. This is consistent with its indirect GABAergic mechanism.

Immune Markers

Several Russian studies document measurable changes in immune markers (interferon production, T-cell activity) following Selank administration. Whether this is clinically meaningful in non-immunocompromised subjects is unclear.

What Is Not Established

• Head-to-head comparison with approved anxiolytics in Western RCT-quality trials
• Long-term safety profile in healthy subjects with chronic use
• Bioavailability via intranasal route — measured in animals, assumed in humans
• Whether the anxiolytic effect is sustained with repeated dosing or diminishes with tolerance
• Optimal cycle length and off-period requirements

Dosing Protocols (Research Context)

Cycle: Russian clinical protocols run 10–14 days. Researcher protocols: 14–21 days on, 7–14 days off.

Timing: On-demand or scheduled. As an anxiolytic, Selank can be used situationally (before high-stress contexts) or as a daily protocol. The short effective half-life (CNS effects several hours; plasma clearance within minutes) means timing is flexible.

With Semax: When stacking with Semax, administer both simultaneously or within a few minutes. See the Cognitive Stack guide for the combined protocol.

Administration

Supplied as a ready-to-use nasal solution. Same technique as Semax — tilt head back, drops into each nostril, gentle inhalation. No reconstitution required.

Storage: Refrigerate at 2–8°C. Do not freeze. Selank nasal solutions are typically more temperature-sensitive than lyophilised powders — check supplier-specific stability data.

Summary

Selank occupies a unique pharmacological niche: an anxiolytic that is non-sedating, non-dependent, and cognitively neutral to slightly positive. The Russian clinical evidence base is real, if not by Western standards. The mechanism — enkephalin stabilisation and indirect GABAergic modulation — is distinct from all approved pharmaceutical anxiolytics and explains the unusual profile. For researchers interested in anxiety without the trade-offs of conventional anxiolytics, Selank is the most evidence-supported option in the peptide literature.

See also: Selank data page · Cognitive Stack: Semax + Selank